Sarissa Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sarissa Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000	Closed	-$177K	–	11
2021 Q2	$177K	Hold	1,000	–	–	0.01%	12
2021 Q1	$164K	Sell	1,000 -927,100	-100%	-$153M	0.02%	13
2020 Q4	$153M	Hold	928,100	–	–	15.63%	4
2020 Q3	$132M	Hold	928,100	–	–	15.58%	2
2020 Q2	$102M	Buy	928,100 +163,100	+21%	+$18M	11.39%	4
2020 Q1	$76.3M	Buy	765,000 +321,500	+72%	+$41.6M	9.73%	5
2019 Q4	$66.2M	Buy	443,500 +201,500	+83%	+$27.4M	5.5%	9
2019 Q3	$31M	Buy	242,000 +45,500	+23%	+$6.1M	3.89%	7
2019 Q2	$28M	Buy	196,500 +96,500	+97%	+$13M	3.49%	7
2019 Q1	$14.3M	Buy	+100,000	New	+$13M	2.15%	9

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Sarissa Capital Management's JAZZ Position: Q3 2021 in Review

Sarissa Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 1,000 shares — an estimated $177K sold.

Sarissa Capital Management first reported a position in JAZZ in Q1 2019 and held it in 10 quarters. The position peaked at $153M in Q4 2020. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Sarissa Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Sarissa Capital Management sold 1,000 Jazz Pharmaceuticals shares in Q3 2021, an estimated $177K.
Sarissa Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 10 quarters.
Sarissa Capital Management's Jazz Pharmaceuticals position peaked at $153M in Q4 2020.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Sarissa Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.